Rebiotix is on the forefront of an exciting potential medical breakthrough
Harnessing the Power of the Human Microbiome
Rebiotix Inc., a Ferring Company, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome.
The company is on the forefront of an exciting potential medical breakthrough with our MRT™ drug platform. The MRT drug platform is leveraged to develop formulations consisting of live microbes, which are evaluated through our clinical program for the formulation’s ability to address challenging diseases.
Rebiotix looks to deliver on the promise of restoring the gut microbiota via standardized and stabilized investigational drugs that have been developed and tested under the auspices of a regulatory authority.
Key Milestones in Harnessing the Power of the Human Microbiome
Rebiotix was founded
Pre-Investigational New Drug (IND) meeting with FDA for RBX2660
FDA IND granted
Fast Track designation granted
PUNCH CD Phase 2 trial enrolled for RBX2660 to treat recurrent Clostridium difficile
FDA Orphan Drug designation granted
Results of PUNCH CD announced
PUNCH CD 2 (phase 2b) trial initiated
Development of oral formulation, RBX7455, started
Oral formulation Drug Master File (DMF) filed with FDA
Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile
Phase 3 PUNCH CD3 initiated Q3 2017
Phase 3 Open Label PUNCH CD3-OLS Initiated Q2 2019